Impact BioMedical Inc

Impact BioMedical insider sales reveal portfolio rebalancing, not distress – with promising Linebacker and Laetose trials driving future growth prospects.

Impact BioMedical insider sale: 50,000 shares at $0.65 amid 27% rally. Learn how regulatory milestones, partnership deals, and market volatility shape its high‑risk, high‑potential biotech upside.